Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932735 | 0.88 | METAP2 (0.32) | METAP2HSP90AA1HSP90AB1 | |
| SCHEMBL13620870 | 0.86 | HSP90AA1 (0.39) | LGALS8METAP2HSP90AA1HSP90AB1 | |
| SCHEMBL10259547 | 0.86 | HSP90AA1 (0.39) | LGALS8METAP2HSP90AA1HSP90AB1 | |
| SCHEMBL10306468 | 0.86 | HSP90AA1 (0.39) | LGALS8METAP2HSP90AA1HSP90AB1 | |
| SCHEMBL13609342 | 0.86 | HSP90AA1 (0.39) | LGALS8METAP2HSP90AA1HSP90AB1 | |
| SCHEMBL7885428 | 0.86 | HSP90AA1 (0.39) | LGALS8METAP2HSP90AA1HSP90AB1 | |
| SCHEMBL7882575 | 0.78 | HSP90AA1 (0.36) | METAP2HSP90AA1HSP90AB1 | |
| SCHEMBL10260098 | 0.78 | HSP90AA1 (0.36) | METAP2HSP90AA1HSP90AB1 | |
| SCHEMBL10306466 | 0.78 | HSP90AA1 (0.36) | METAP2HSP90AA1HSP90AB1 | |
| SCHEMBL13620869 | 0.78 | HSP90AA1 (0.36) | METAP2HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | LGALS8 266/4885METAP2 3911/4885HSP90AA1 4/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | LGALS8 4219/4885METAP2 4279/4885HSP90AA1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.